Gene therapy retreatment aims to cut surgeries for rare throat tumor condition
NCT ID NCT06538480
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a gene therapy called Zopapogene imadenovec (Zopa) in 30 adults with recurrent respiratory papillomatosis (RRP), a condition causing non-cancerous throat tumors that often require repeated surgeries. One group will check how the virus used in the therapy leaves the body, while another group will see if retreatment can eliminate the need for surgery for a full year. The goal is to control the disease and reduce the burden of frequent procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAPILLOMAVIRIDAE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institute of Health
RECRUITINGBethesda, Maryland, 20892, United States
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45267, United States
-
Winship Cancer Institute, Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vaccine plus a Blood-Vessel blocker stop airway growths from coming back?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Immune drug shows promise against rare HPV throat tumors
- Experimental vaccine aims to tame rare throat tumor disease
- HPV vaccine lesson in one school may raise consent rates
- New drug combo aims to reduce surgeries for rare HPV throat condition